Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Frequently asked questions
What sector does PHARMING GRP SP. ADRS (PHG) operate in?
PHARMING GRP SP. ADRS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is PHARMING GRP SP. ADRS (PHG) current stock price?
As of the latest data, PHARMING GRP SP. ADRS stock price is €10.10, with a previous close of €10.50. PHARMING GRP SP. ADRS lost -€0.40 in the last trading session, representing a -3.81% loss.
What is PHARMING GRP SP. ADRS (PHG) current market capitalization?
PHARMING GRP SP. ADRS market cap is approximately 714.86 million.
What is PHARMING GRP SP. ADRS (PHG) Earnings Per Share (EPS)?
The trailing EPS is €0.12.
What is PHARMING GRP SP. ADRS (PHG) Price-to-Earnings (P/E) ratio?
PHARMING GRP SP. ADRS current P/E ratio is 84.17.
Does PHARMING GRP SP. ADRS (PHG) pay dividends?
No. PHARMING GRP SP. ADRS does not pay a dividend.
What is PHARMING GRP SP. ADRS (PHG) beta (volatility) score?
PHARMING GRP SP. ADRS has a beta of 0.074, indicating lower volatility than the overall market.
